VRC 311: A Phase 1 Open Label, Dose-Escalation Clinical Trial to Evaluate the Safety and Immunogenicity of a Virus-Like Particle (VLP) Chikungunya Vaccine, VRC-CHKVLP059-00-VP, in Healthy Adults.
Phase of Trial: Phase I
Latest Information Update: 18 Jan 2017
At a glance
- Drugs VRC-CHKVLP059-00-VP (Primary)
- Indications Chikungunya virus infections
- Focus Adverse reactions; Therapeutic Use
- 01 Apr 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 13 Jun 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 20 Mar 2012 Additional lead trial investigator identified as reported by ClinicalTrials.gov.